Summary Information about Bacillus amyloliquefaciens strain MOL1350, and Bacillus lentus strain PL2958 Microbial Commercial Activity Notices (MCANs), submitted by Novo Nordis Biochem North America, Inc.
On March 16, 1998, the Office of Pollution Prevention and Toxics (OPPT) received the first two Microbial Commercial Activity Notices (MCANs) under the biotechnology regulations promulgated under the Toxic Substances Control Act (62 FR 17910 (April 11, 1997)). The MCANs, submitted by Novo Nordisk Biochem North America, Inc., were given OPPT designations J98-001 and J98-002. The MCAN microorganisms are, respectively, Bacillus amyloliquefaciens strain MOL1350, and Bacillus lentus strain PL2958. B. amyloliquefaciens strain MOL1350 will be used in the commercial biosynthesis of an alpha-amylase that is more thermally stable than the wild-type enzyme. B. lentus strain PL2958 will be used in the commercial biosynthesis of a subtilisin protease. The microorganisms will be removed from the final enzyme products. The main commercial application for both enzymes is in the detergent industry.
For a copy of the nonconfidential version of the MCAN, please contact the TSCA Non-Confidential Information Center (NCIC) by phone at 202-566-0280 , or by fax at 202-566-0282.
Last Revision: March 6,